Home/Filings/4/0000950170-24-005561
4//SEC Filing

van Dijk Marcus Antonius 4

Accession 0000950170-24-005561

CIK 0001840229other

Filed

Jan 17, 7:00 PM ET

Accepted

Jan 18, 8:00 PM ET

Size

7.9 KB

Accession

0000950170-24-005561

Insider Transaction Report

Form 4
Period: 2024-01-16
van Dijk Marcus Antonius
Chief Technology Officer
Transactions
  • Award

    Stock Option

    2024-01-16+171,078171,078 total
    Exercise: $0.87Exp: 2034-01-16Common Stock (171,078 underlying)
  • Award

    Stock Option

    2024-01-16+15,00015,000 total
    Exercise: $0.87Exp: 2034-01-16Common Stock (15,000 underlying)
Footnotes (2)
  • [F1]An option to purchase Common Stock was granted to Dr. van Dijk on January 16, 2024 and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. The option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter.
  • [F2]An option to purchase Common Stock was granted to Dr. van Dijk on January 16, 2024 for his performance in 2023, and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. Half of the options will vest on June 27, 2024 and half of the options will vest on September 27, 2024.

Documents

1 file

Issuer

MiNK Therapeutics, Inc.

CIK 0001840229

Entity typeother

Related Parties

1
  • filerCIK 0001881659

Filing Metadata

Form type
4
Filed
Jan 17, 7:00 PM ET
Accepted
Jan 18, 8:00 PM ET
Size
7.9 KB